US manufacturer ResMed has completed the acquisition of Texas-based medical device firm Inova Labs, which is involved in developing oxygen therapy products.

Although initially announced last month January, the deal’s terms have not been disclosed.

The deal allows ResMed to expand its care offerings and solutions to treat people with chronic obstructive pulmonary disease (COPD).

Currently, ResMed’s respiratory care offerings include products such as the AirCurve 10 series of cloud-connected non-invasive ventilators, the Stellar series of non-invasive ventilators, and the Astral series.

"This acquisition is an important step to reach our goal of improving 20 million lives by 2020."

Astral is a lightweight non-invasive life-support platform with internal and external batteries that provide up to 24 hours of freedom for patients.

ResMed CEO Mick Farrell said: "We are excited to complete this acquisition, which expands our offerings and solutions to address a global COPD epidemic impacting tens of millions of people.

"This acquisition is an important step to reach our goal of improving 20 million lives by 2020."

The acquisition adds ResMed with both portable oxygen concentrators and necessary stationary options for the home.

Inova Labs produces LifeChoice Activox, which is a lightweight and portable oxygen concentrator that provides enhanced battery life for greater freedom and mobility.

The company’s portfolio also includes Activox DUO2, which is claimed to be the industry’s first fully integrated stationary and portable oxygen concentrator system.

Last October, ResMed acquired non-invasive ventilation and sleep-disordered breathing medical devices and accessories provider, Curative Medical.

Established in 2008, Curative designs and produces medical devices for sleep-disordered breathing and COPD.

With operations in more than 100 countries, ResMed is focused on developing devices for the diagnosis, treatment and management of sleep-disordered breathing, COPD and other chronic conditions.